Fig. 2.

Correlation between tumor mutational burden and objective response rate with anti-PD-1 or anti-PD-L1 therapy in 27 tumor types. [Reprinted with permission from https://www.nejm.org/doi/10.1056/NEJMc1713444]. Shown are the median numbers of coding somatic mutations per megabase (MB) of DNA in 27 tumor types or subtypes among patients who received inhibitors of programmed death 1 (PD-1) protein or its ligand (PD-L1), as described in published studies for which data regarding the objective response rate are available. The number of patients who were evaluated for the objective response rate is shown for each tumor type (size of the circle), along with the number of tumor samples that were analyzed to calculate the tumor mutational burden (degree of shading of the circle). Data on the x axis are shown on a logarithmic scale. MMRd denotes mismatch repair-deficient, MMRp mismatch repair-proficient, and NSCLC non-small cell lung cancer. A significant correlation between the tumor mutational burden and the objective response rate (P < 0.001) to the IO was demonstrated by the above study [75]